Association Between Androgenetic Alopecia and Glucagon-Like Peptide-1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study
July 2025
in “
International Journal of Dermatology
”
Research cited in this study
2 / 2 resultsresearch Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study
GLP-1 RA medications may be linked to hair loss.
research Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.
Similar Research
5 / 1000+ resultsresearch 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
This study found that glucagon-like peptide-1 receptor agonist therapy was independently associated with an increased incidence of non-scarring hair loss, including telogen effluvium and androgenic alopecia, in adults but not alopecia areata.
research Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
This study found that GLP-1 receptor agonists are linked to a significant 40% increased risk of non-scarring alopecia, which may result from weight loss-induced micronutrient deficiency.
research Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
This study found that GLP-1 receptor agonists are linked to a 40% increased risk of non-scarring alopecia in adults, mainly due to weight loss-induced micronutrient deficiencies, with semaglutide and tirzepatide showing the highest hair loss signals.
research Glucagon-Like Peptide-1 Receptor Agonists and Hair Loss: Current Evidence and Potential Mechanisms
This literature review highlights a potential but uncertain link between GLP-1 receptor agonist therapy for type 2 diabetes and obesity and hair loss, with variations among different medications.